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Introduction {#sec005}
============

Elevated LDL-C (blood cholesterol in a complex with low density lipoprotein, LDL) is a well characterized risk factor for cardiovascular disease, including serious events such as stroke or heart attack.\[[@pone.0199645.ref001]\] Therapies recommended to reduce LDL-C include lifestyle modification (diet, smoking cessation) and aerobic exercise which may include tendon loading activities such as walking, jogging or running.\[[@pone.0199645.ref002],[@pone.0199645.ref003]\]

In addition to prescription of exercise and lifestyle modification, statins are a widely used class of medications which can inhibit cholesterol production in the liver and thereby lead to lowered LDL-C.\[[@pone.0199645.ref001]\] Statins are therefore commonly used in the management of individuals with hypercholesterolemia, and are generally well tolerated. However, a minority of individuals experience side effects which can include diabetes mellitus and myalgia.\[[@pone.0199645.ref004]\]

Several case reports (e.g. \[[@pone.0199645.ref005]\], and a formal review of incidents reported in a pharmacovigilance database,\[[@pone.0199645.ref006]\] have suggested that Achilles tendon rupture might be among the side effects of statins. In keeping with this possibility, a number of laboratory studies have demonstrated a direct impairment of collagen metabolism in response to statin exposure, including reduced type I collagen levels and increased expression and activity of several matrix metalloproteinases.\[[@pone.0199645.ref007],[@pone.0199645.ref008],[@pone.0199645.ref009]\] However, the best evidence available to date comprises a propensity-score matched study of over 500,000 statin-users in the UK: in that study, statin use was not associated with an increased risk of Achilles tendon rupture.\[[@pone.0199645.ref010]\] In their discussion, the authors noted that their study could not exclude the possibility that statins might lead to milder tendon injury such as tendinopathy.\[[@pone.0199645.ref010]\] To our knowledge, no study to date has directly examined the Achilles tendon for signs of subclinical degeneration in regular statin users.

Ultrasound tissue characterization (UTC) uses automated algorithms to analyze three-dimensional digital images of a tendon, and assigns each pixel a value from I to IV, with higher values representing more highly aligned collagen, as indicated by stability of pixel brightness across adjacent transverse scans. UTC is able to detect the subtle structural differences among Achilles tendons which occur with gender,\[[@pone.0199645.ref011]\] diabetes,\[[@pone.0199645.ref012]\] regional variations in anatomy or pathology \[[@pone.0199645.ref011],[@pone.0199645.ref013]\], and in response to exercise \[[@pone.0199645.ref014],[@pone.0199645.ref015]\], all of which are characterized by a relative reduction in % type I echoes. Using UTC, we set out to test the hypothesis that statin users would demonstrate impaired Achilles tendon structure, including cross-sectional area and longitudinal collagen organization (as indicated by UTC: % type I echoes). We also examined the relation of BMI and age with these two Achilles tendon structural variables, because they are both recognized risk factors for the development of Achilles tendon injury \[[@pone.0199645.ref016],[@pone.0199645.ref017]\].

Methods {#sec006}
=======

Setting {#sec007}
-------

All study visits took place at the Centre for Hip Health and Mobility (CHHM) in Vancouver, British Columbia. Recruitment and data collection occurred from May 10 2015 to February 17 2017. The study protocol was reviewed and approved by the UBC Clinical Research Ethics Board (H14-01808).

Participants {#sec008}
------------

All participants provided written informed consent. Statin users were recruited primarily through a cardiac rehabiliation program offered by the Centre for Cardiovascular Health (a division of Vancouver Coastal Health). To be included, participants had to have been taking any type of statin for at least one year. We excluded participants who had taken oral corticosteroids or fluoroquinolones in the past year, had any condition which would impact Achilles tendon health including diabetes, gout, rheumatoid arthritis, whose BMI was over 35 kg/m2, who had peripheral edema in the lower extremities, who had pain or mobility issues (e.g. the use of a cane or walker), or who were not interested or committed to attending the study visit. Eligible participants in the statin group were informed about the study through word of mouth by clinic staff, or by mail and phone. Statin users in the general community were also recruited by placing posters placed around the community. Participants in the comparison group of statin non-users had to have never taken a statin, and the same exclusion criteria applied. The comparison group was recruited from the Centre for Cardiovascular Health in person and through mail/phone contact, and additional comparison group participants were recruited by word of mouth recruiting at our research centre, at Vancouver community groups (e.g. Prime Timers, West Ender), and through posters placed around the community and online.

Variables {#sec009}
---------

### Demographic variables {#sec010}

We measured participants' weight and height at the time of the ultrsaound scan, and asked them their age in years. Participants were categorized using the short form of the International Physical Acticvity Questionnaire (IPAQ) as engaging in low, medium, or high levels of physical activity. The IPAQ questionnaire asks people to report on their physical activity levels over the preceding seven days. This questionnaire demonstrates excellent reliability \[[@pone.0199645.ref018]\], although the limitations of using self-report measures to characterize physical activity levels, particuarly among older populations such as in the current study, are acknowledged \[[@pone.0199645.ref019]\]; people tend to over-report their physical activity levels.

### Collagen organization {#sec011}

Subjects lay prone on an examination bed with their feet placed on a foot and ankle stabilizer to stabilize and position the Achilles tendon. Both the left and right tendons were scanned; each tendon was scanned in duplicate. A 10MHz linear array probe (Smartprobe 10L5; Terason 2000, Teratech, USA) was connected to a robotic tracker (UTC technologies); the tracker was clamped to a pole to prevent movement artefact. The tracker was programmed to capture multiple transverse 2-D images every 0.2mm over a total Achilles tendon length of 12cm. The images were collected and stored on a computer (MacbookPro) running UTC imaging algorithms to produce a 3-D image for tomographic visualization in the transverse, sagittal, and coronal planes; the algorithms analyzed pixel stability in the longitudinal plane using a window size of 25 to discriminate four echo types \[[@pone.0199645.ref019]\], \[[@pone.0199645.ref020]\]. The more longituidnally well-organized the collagen, the greater the type I echo percentage. The examiner determined the landmark (2cm from the calcaneal insertion) in the sagittal plane. The tendon border was outlined (referred to as a contour) at 2mm proximal and distal to the landmark. The two contours were interpolated to create a 4mm long region of interest used for tissue characterization. The percentage of type I echoes were calculated within the region of interest. The test-retest reliability of type I echo percentage on separate days, based on a study of 10 individuals, yielded an ICC of 0.90.

### Achilles tendon cross-sectional area {#sec012}

Using the same ultrasound scans generated as described above, the borders of the Achilles tendon was contoured in the transverse plane and the cross-sectional area image analyzed in ImageJ. The distance measures provided by the UTC were calibrated in ImageJ against scans of a phantom which contained regularly spaced 0.1mm diameter metal pins (CIRS 050).

### Attempts to limit bias {#sec013}

The study was designed and the report was prepared using the Strobe checklist for reporting of cohort studies \[[@pone.0199645.ref020]\]. We attempted to limit sampling bias by recruiting the comparison group from the same clinic as the statin users, although it was necessary to supplement this by recruiting from the community as well. To limit sex/gender and age bias, we decided *a priori* to assemble equivalent sized ST and CG groups with equal numbers of males and females and of similar age. To limit the possibility of assessor bias during ultrasound scanning, we employed a "hands-off" approach as described above, where the ultrasound probe was clamped into position and not manipulated by the researcher. To control for bias during analysis, all images were de-identified and analyzed in a batch containing scans from statin and control groups, to ensure the researcher was blind to participant group.

### Study size {#sec014}

We planned to recruit during a time period which was consistent with the timeline of the first author's MSc program timeline, and all eligible participants who were identified during that time period were enrolled. Assuming that the variability for cross-sectional area observed in this study (10.8 mm^2^) represents the true population variability, in order to detect a difference in cross-sectional area of 20% between the statin users and comparison group with a p-value of 0.01, a two-sided independent samples t-test would have 95% power with a sample of 30 per group.

### Statistical analysis {#sec015}

The experimental unit in this study was the individual, who either was or was not exposed to statins. It was assumed that the ingestion of statins could affect either the right or left tendon, therefore the values of the two tendons were averaged for each structural variable. We used the Shapiro-Wilks test to determine whether data were normally distributed. For normally distributed data (age, BMI, cross-sectional area), we used parametric tests (independent t-tests, and Pearson's correlation coefficient), and reported means and standard deviations. For non-normally distributed data (type I echoes) we used non-parametric tests (Mann-Whitney U test, Spearman's Rho) and reported the mean and interquartile range (IQR). We used two-tailed tests (p = 0.05) to compare the tendon structural variables between statin users and the comparison group, because one could argue either that statin use would lead to tendon atrophy, or to injury and therefore expansion of the cross-sectional area. Because we expected women's tendons to be smaller and contain a lower precentage of type I echoes than men's tendons, we conducted 1-tailed tests to examine these comparisons, as an internal control of the measurement techniques. We also calculated correlation coefficients (Pearson's r or Spearman's r~s~, as stated above) to examine the potential relation of BMI and age to the dependent variables in the combined cohort (ST and CG). Upon noting a correlation between BMI and type I echoes, we conducted a Kruskal-Wallis test to compare the distribution of type I echoes among those of normal BMI (18--24.9), overweight (25.0--29.9), and obese (30--35). Finally, we examined duration of time on statins (self-reported), and found this data to be non-normally distributed; we applied Spearman's rank-order test to see if this variable was correlated with tendon cross-sectional area or type 1 echoes. All results are reported to two significant digits.

Results {#sec016}
=======

Participants {#sec017}
------------

### Recruitment {#sec018}

Through the Cardiac Rehabilitation Centre, 378 patients were approached in person (n = 250) or were mailed the study information (n = 128). Of those who were approached in person, 224 met one or more exclusion criteria, 2 were interested and signed the consent form but then withdrew before participating, and 24 participants (21 ST and 3 CG) enrolled. An additional 129 eligible participants were mailed study information and then contacted by phone: 92 were not interested, 6 could not be reached, 10 met one or more exclusion criteria, and 21 participants (13 ST users and 8 CG) enrolled. Twenty-four individuals responded to paper or online advertisements: 4 met one or more exclusion criteria, 2 statin non-users were not enrolled because they were not the desired gender to achieve balanced groups, and 18 participants (1 ST, 17 CG) enrolled. Word of mouth recruitment led us to screen an additional 18 people, of which 8 participants (controls) met the study criteria and enrolled. Prior to any analysis and without any reference to any details of their study files, 2 very elderly statin users were removed because CG participants in the same age range had not been recruited, and 3 CG participants (women) were removed to maintain gender balance in the ST and CG groups. This recruitment method resulted in the inclusion of 33 statin users and 33 in the comparison group. Data from all 66 subjects was complete (no missing data) and all was included in the analysis.

### Demographic and descriptive data {#sec019}

The subject data is shown in [Table 1](#pone.0199645.t001){ref-type="table"}. Data from all included participants was analyzed, with no missing data. All of the statin users (n = 33) stated that they were consistently taking their statin (adherent to treatment) and had been on their statin for at least a year. The median duration of statin use was 4.5 years (IQR 6.25), and this duration was not corelated to tendon cross-sectional area or % Type 1 echoes. All participants had normal cholesterol levels on their last available lipid test. All of the control subjects (n = 33) had never taken a statin medication.

10.1371/journal.pone.0199645.t001

###### Comparison of statin users and a comparison group of statin non-users.

![](pone.0199645.t001){#pone.0199645.t001g}

  Variable                                        All participants   Statin users   Comparison group   p-value[\*](#t001fn002){ref-type="table-fn"}
  ----------------------------------------------- ------------------ -------------- ------------------ ----------------------------------------------
  N                                               66                 33             33                 
  Age, years: mean (SD)                           66 (9)             69 (10)        63 (8)             **0.0054**
  Men                                             58                 29             29                 
  Women                                           8                  4              4                  
  BMI, kg/m2: mean (SD)                           27 (3.7)           27 (3.3)       27 (4.1)           0.61
  Physical activity levels: low, moderate, high   7, 31, 28          4, 14, 15      3, 17, 13          
  Tendon cross-sectional area, mm^2^: mean (SD)   60 (11)            60 (13)        60 (9)             0.95
  \% Type I echoes: median (IQR)                  72 (13)            70 (10)        74 (13)            0.059

BMI: Body mass index. SD: Standard deviation. IQR: Interquartile range.

\* For normally distributed data (age, BMI, cross-sectional area), independent t-tests were used. For non-normally distributed data (% Type I echoes), a Mann-Whitney U test was used.

As expected, women's Achilles tendons were slightly smaller (54 (8.9) mm^2^ vs 61 (11) mm^2^, p = 0.064) and contained a lower percentage of type I echoes (57 (13) % vs 70 (9.2), p = 0.0063), despite being of equivalent age, BMI and activity level as men.

As seen in [Table 1](#pone.0199645.t001){ref-type="table"}, the statin group was slightly older than the comparison group (despite our effort to recruit a control group of similar age to the statin users). However, age was not correlated with either tendon cross-sectional area (r = -0.15, n = 66) or percentage type I echoes (r~s~ = -0.16, n = 66).

There was a negative correlation between BMI and the percentage of type I echoes (r~s~ = -0.25, p = 0.011, n = 66). Because BMI was not different between statin users and the comparison group ([Table 1](#pone.0199645.t001){ref-type="table"}), we examined the influence of BMI category in the entire cohort (n = 66) according to standard criteria ([Fig 1](#pone.0199645.g001){ref-type="fig"}). This analysis demonstrated that the Achilles tendons from obese individuals (n = 11) displayed a reduced percentage of type I echoes.

![Body mass index and collagen organization.\
The entire cohort (n = 66) was categorized as having a body composition that was normal (18.5 to 24.9, n = 24), overweight (25 to 29.9, n = 21) or obese (30+, n = 11).\[[@pone.0199645.ref021]\] Statin users are shown as open circles, controls are yellow. Obese individuals (comprising 5 male statin-users, 1 female statin user, and 5 male comparison participants,) demonstrated a reduced collagen organization (Kruskal-Wallis H = 7.4, df = 2, p = 0.02) compared to those of normal body weight.](pone.0199645.g001){#pone.0199645.g001}

Discussion {#sec020}
==========

This study did not identify any influence of statin use on Achilles tendon cross-sectional area or collagen organization (UTC: percentage type I echoes). These results are encouraging for health professionals working in cardiovascular rehabilitation who may wish to prescribe load-bearing exercise as part of a multidisciplinary intervention for people with hypercholesterolemia.\[[@pone.0199645.ref002],[@pone.0199645.ref003]\]

Using ultrasound tissue characterization, we detected a negative moderate correlation between BMI and collagen organization in the Achilles tendon, which was an expected finding given that increasing BMI is a recognized risk factor for Achilles tendinopathy \[[@pone.0199645.ref022]\] and tendon rupture \[[@pone.0199645.ref017]\], both of which are often preceded by detectable degenerative changes in the Achilles tendon collagenous matrix.\[[@pone.0199645.ref023]\] The mechanism for the relation between excessive body weight and Achilles tendon pathology has not yet been elucidated, but may involve both mechanical and biological effects (reviewed in \[[@pone.0199645.ref024]\]).

This study is limited by its cross-sectional nature: statin-users were assessed at least 1 year after commencing lipid-lowering therapy. It is possible that participants who initially presented with dyslipidemia may have experienced an improvement in tendon structure as lipid levels normalized in response to statins, exercise and lifestyle management.\[[@pone.0199645.ref025]\] Furthermore, it would have been helpful to know whether tendon properties were related to lipid levels at baseline, and to examine the relation of lipid profile with tendon structure in the comparison group. Although not the primary focus of this study, such a relation would have been of interest given that LDL-C and TC levels are, on average, higher in people with tendon pathology.\[[@pone.0199645.ref026]\] The mechanism may involve an inhibitory effect of oxidized LDL on tenocytes.\[[@pone.0199645.ref027]\]

The generalizability of this study is limited to relatively sedentary individuals of advanced age. We cannot extrapolate with regard to the potential impact of statins in younger or middle-aged individuals engaged in more elite-level sporting activities who are more prone to develop Achilles tendinopathy. This group may warrant separate focus in a future study.

In conclusion, we found no difference in the Achilles tendon structure of statin users compared with a group of non-users, as visualized with ultrasound tissue characterization. These results are in keeping with a large, well-controlled epidemiological study which demonstrates a lack of negative impact of statins on tendon health.\[[@pone.0199645.ref010]\]

Supporting information {#sec021}
======================

###### Primary data used to test the hypotheses in the current study.

(XLSX)

###### 

Click here for additional data file.
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